Entrada Therapeutics
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).
Stock Symbol: TRDA
Stock Exchange: NASDAQ
CONNECT
“Most targets for drug development are actually intracellular,” says Dipal Doshi, President and CEO of Entrada Therapeutics. “Think about how many drugs can be made that can help patients if we can figure out a way to effectively get inside the cell…that’s why Entrada’s important.”
38 articles about Entrada Therapeutics
-
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
4/4/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt “Bernie” Zeiher to its Board of Directors, effective immediately.
-
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
3/29/2023
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a virtual fireside chat during the Guggenheim Genomic Medicines and Rare Disease Conference on Tuesday, April 4, 2023 at 9:00 a.m. Eastern Time.
-
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
3/6/2023
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the fourth quarter and full year ending December 31, 2022 and highlighted recent business updates.
-
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
2/27/2023
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate on the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference.
-
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
2/9/2023
Entrada Therapeutics, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.
-
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
1/9/2023
Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, announced the selection of a second clinical candidate within its Duchenne franchise, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable.
-
The FDA placed a clinical hold on Entrada's experimental DMD candidate. -
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
12/19/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.
-
Vertex Pharmaceuticals agreed to a collaboration deal with Entrada Therapeutics. The two companies announced a collaboration to develop an intracellular Endosomal Escape Vehicle. -
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
12/8/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1).
-
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
11/22/2022
Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 5th Annual HealthCONx Virtual Conference on Tuesday, November 29, 2022 at 3:55 p.m. Eastern Time.
-
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
11/7/2022
Entrada Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates.
-
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
8/11/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent business updates.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers. -
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
7/19/2022
Entrada Therapeutics, Inc. today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately.
-
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
6/1/2022
Entrada Therapeutics, Inc. announced that the Company will participate in-person at the Goldman Sachs Global Healthcare Conference.
-
Entrada Therapeutics Reports First Quarter 2022 Financial Results
5/12/2022
Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and highlighted recent business updates.
-
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
5/11/2022
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today presented updates to its two lead programs at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics Conference.
-
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference - May 10, 2022
5/10/2022
Entrada Therapeutics, Inc. announced that Dipal Doshi, President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference.
-
Dozens of life sciences companies are relocating to accommodate more employees and production capacities.